Debora Pedrazzoli1, Andrew Siroka2, Delia Boccia1, Frank Bonsu3, Kenneth Nartey4, Rein Houben1, Josephine Borghi5. 1. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. 2. World Health Organization, Global Tuberculosis Programme, Geneva, Switzerland. 3. National Tuberculosis Control Programme, Ghana Health Service, Accra, Ghana. 4. Dodowa Health Research Centre, Dodowa, Ghana. 5. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Abstract
OBJECTIVES: Tuberculosis (TB) is known as a disease of the poor. Despite TB diagnosis and care usually being offered for free, TB patients can still face substantial costs, especially in the context of multi-drug resistance (MDR). The End TB Strategy calls for zero TB-affected families incurring 'catastrophic' costs due to TB by 2025. This paper examines, by MDR status, the level and composition of costs incurred by TB-affected households during care seeking and treatment; assesses the affordability of TB care using catastrophic and impoverishment measures; and describes coping strategies used by TB-affected households to pay for TB care. METHODS: A nationally representative survey of TB patients at public health facilities across Ghana. RESULTS: We enrolled 691 patients (66 MDR). The median expenditure for non-MDR TB was US$429.6 during treatment, vs. US$659.0 for MDR patients (P-value = 0.001). Catastrophic costs affected 64.1% of patients. MDR patients were pushed significantly further over the threshold for catastrophic payments than DS patients. Payments for TB care led to a significant increase in the proportion of households in the study sample that live below the poverty line at the time of survey compared to pre-TB diagnosis. Over half of patients undertook coping strategies. CONCLUSION: TB patients in Ghana incur substantial costs, despite free diagnosis and treatment. High rates of catastrophic costs and coping strategies in both non-MDR and MDR patients show that new policies are urgently needed to ensure TB care is actually affordable for TB patients.
OBJECTIVES: Tuberculosis (TB) is known as a disease of the poor. Despite TB diagnosis and care usually being offered for free, TB patients can still face substantial costs, especially in the context of multi-drug resistance (MDR). The End TB Strategy calls for zero TB-affected families incurring 'catastrophic' costs due to TB by 2025. This paper examines, by MDR status, the level and composition of costs incurred by TB-affected households during care seeking and treatment; assesses the affordability of TB care using catastrophic and impoverishment measures; and describes coping strategies used by TB-affected households to pay for TB care. METHODS: A nationally representative survey of TB patients at public health facilities across Ghana. RESULTS: We enrolled 691 patients (66 MDR). The median expenditure for non-MDR TB was US$429.6 during treatment, vs. US$659.0 for MDR patients (P-value = 0.001). Catastrophic costs affected 64.1% of patients. MDR patients were pushed significantly further over the threshold for catastrophic payments than DS patients. Payments for TB care led to a significant increase in the proportion of households in the study sample that live below the poverty line at the time of survey compared to pre-TB diagnosis. Over half of patients undertook coping strategies. CONCLUSION: TB patients in Ghana incur substantial costs, despite free diagnosis and treatment. High rates of catastrophic costs and coping strategies in both non-MDR and MDR patients show that new policies are urgently needed to ensure TB care is actually affordable for TB patients.
Authors: N Stracker; C Hanrahan; L Mmolawa; B Nonyane; R Tampi; A Tucker; N West; L Lebina; N Martinson; D Dowdy Journal: Int J Tuberc Lung Dis Date: 2019-06-01 Impact factor: 2.373
Authors: Susan M McAllister; Bony Wiem Lestari; Trudy Sullivan; Panji Fortuna Hadisoemarto; Nur Afifah; Rosye Arosdiani Apip; Megan Murray; Philip C Hill; Bachti Alisjahbana Journal: Am J Trop Med Hyg Date: 2020-09 Impact factor: 2.345
Authors: Collins Timire; Mkhokheli Ngwenya; Joconiah Chirenda; John Z Metcalfe; Katharina Kranzer; Debora Pedrazzoli; Kudakwashe C Takarinda; Peter Nguhiu; Geshem Madzingaidzo; Kwenzikweyinkosi Ndlovu; Tawanda Mapuranga; Morna Cornell; Charles Sandy Journal: Trop Med Int Health Date: 2021-08-03 Impact factor: 2.622